1. Home
  2. PLSE vs TRVI Comparison

PLSE vs TRVI Comparison

Compare PLSE & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$19.11

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$14.16

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
TRVI
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
PLSE
TRVI
Price
$19.11
$14.16
Analyst Decision
Buy
Strong Buy
Analyst Count
1
11
Target Price
$22.00
$21.55
AVG Volume (30 Days)
224.7K
1.6M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$5.38
52 Week High
$26.30
$16.12

Technical Indicators

Market Signals
Indicator
PLSE
TRVI
Relative Strength Index (RSI) 41.63 58.42
Support Level $17.32 $10.07
Resistance Level $20.40 $16.12
Average True Range (ATR) 1.43 0.87
MACD -0.44 -0.09
Stochastic Oscillator 13.73 40.86

Price Performance

Historical Comparison
PLSE
TRVI

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: